AGGAMIN BIOLOGICS
Aggamin is an early-stage biotechnology company founded in early 2010 to develop and commercialize therapies for a variety of vascular diseases. The lead program is focused on preeclampsia — a currently untreatable disease affecting 5% of pregnancies with an annual cost to the U.S health care system of $10 billion. Lead product is an extracorporeal device for preeclampsia that reduces circulating pathogenic proteins to improve maternal and fetal health. The company objectives are to manufacture and commercialize the preeclampsia device as a safe first-in-class treatment for preeclampsia that will control maternal symptoms and extend pregnancy, thus improving both maternal and neonatal outcomes.
AGGAMIN BIOLOGICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2010-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.aggamin.com
Total Employee:
1+
Status:
Active
Total Funding:
7.73 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API Google Maps AJAX Libraries API Google Maps API PostalAddress Schema LocalBusiness Schema Google Maps For Work WebsPlanet
Similar Organizations
Apogee Technology
Apogee is a biotechnology company developing novel drug delivery systems and health sensing solutions to address unmet market health needs.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
TFC Therapeutics
TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
Current Employees Featured
Founder
Investors List
Broadview Ventures
Broadview Ventures investment in Debt Financing - Aggamin Biologics
Official Site Inspections
http://www.aggamin.com Semrush global rank: 12.93 M Semrush visits lastest month: 78
- Host name: 64.71.35.77
- IP address: 64.71.35.77
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aggamin Biologics"
Home - Aggamin
Aggamin is a biotechnology company developing therapies for vascular diseases. The lead program is focused on preeclampsia - a disease affecting 5% of pregnancies with a significant …See details»
Aggamin Biologics - Crunchbase Company Profile & Funding
Aggamin is an early-stage biotechnology company founded in early 2010 to develop and commercialize therapies for a variety of vascular diseases. The lead program is focused on …See details»
Aggamin Company Profile 2024: Valuation, Funding & Investors
Aggamin General Information Description. Developer of biotechnology designed to assist in treating unmet medical needs for vascular diseases. The company's proposed drug therapy …See details»
Aggamin Company Profile | Management and Employees List
Aggamin Profile and History. Aggamin is a biotechnology company founded in 2010 to develop therapies for vascular diseases. The lead program is focused on preeclampsia - a disease …See details»
AGGAMIN PHARMACEUTICALS, LLC - VentureRadar
Aggamin is a biotechnology company founded in 2010 to develop therapies for vascular diseases. The lead program is focused on preeclampsia - a disease affecting 5% of pregnancies with a …See details»
Aggamin Company Profile - Office Locations, Competitors ... - Craft
Aggamin has 5 employees at their 1 location. See insights on Aggamin including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Aggamin Biologics - LinkedIn
Aggamin Biologics is a biotechnology company developing biologic drugs for unmet medical needs. Our research facility is located in the Lasker Audubon Business and Technology …See details»
Aggamin Pharmaceuticals LLC - Company Profile and News
Company profile page for Aggamin Pharmaceuticals LLC including stock price, company news, executives, board members, and contact informationSee details»
Aggamin - Overview, News & Similar companies | ZoomInfo.com
Aggamin contact info: Phone number: (212) 568-4614 Website: www.aggamin.com What does Aggamin do? Aggamin is a biotechnology company founded in 2010 to develop therapies for …See details»
Aggamin Biologics - Products, Competitors, Financials, Employees ...
Headquarters Location. 101 Avenue of the Americas 3rd Floor. New York, New York, 10013, United States. 212-568-4614See details»
Aggamin Biologics - Crunchbase
Aggamin Biologics, Lineage Cell Therapeutics, Soligenix, AZTherapies, OncoHost, and Novellus are all part of the biotechnology sector. Lineage Cell Therapeutics, Soligenix, AZTherapies, …See details»
Aggamin Biologics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Aggamin - Broadview Ventures
Aggamin is an early-stage biotechnology company founded in early 2010 to develop and commercialize therapies for a variety of vascular diseases. The lead program is focused on …See details»
Aggamin CEO and Key Executive Team | Craft.co
Aggamin's Founder is Paul Kussie. Paul Kussie. Founder. Report incorrect company information. Key Executive Tracking. Receive notifications of key executive changes. Get started. …See details»
Aggamin Biologics - Contacts, Employees, Board Members
Aggamin Biologics has 1 current employee profile, Founder, Chief Executive Officer, Manager and Board Member Paul Kussie. Paul Kussie Founder, Chief Executive Officer, Manager and …See details»
Development of a Novel Biologic to Treat Preeclampsia
May 5, 2017 The market for Aggamin?s treatment for preterm PE cases, evident before 34 weeks, is estimated at up to 60,000 patients worldwide, and could later increase to include PE …See details»
Development of a Novel Biologic to Treat Preeclampsia
Sep 25, 2014 In phase II, Aggamin will initiate manufacturing and a safety/toxicology study. PE affects 3-8% of all pregnancies and disease incidence is rising as risk factors such as obesity, …See details»
Paul Kussie - Founder, Chief Executive Officer, Manager
Primary Organization . Aggamin Biologics . Location New York, New York, United States; Regions Greater New York Area, East Coast, Northeastern US; Gender Male; LinkedIn View on …See details»
Cardiovascular and hemodynamic consequences of recombinant …
Dr. Karumanchi is a co-inventor on preeclampsia biomarker patents that are held by Harvard Hospitals. Dr. Karumanchi has a financial interest in Aggamin and reports serving as a …See details»
Aggamin Biologics - Tech Stack, Apps, Patents & Trademarks
Organization. Aggamin Biologics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 10. Monthly …See details»